About this document

1-PRODIGE4 FOLFIRINOX Vs GEMCITABINE by Yves Matos is a document available to read on EtoBox.

A study comparing the efficacy and safety of FOLFIRINOX and gemcitabine as first-line therapies for metastatic pancreatic cancer found that FOLFIRINOX significantly improved overall survival (11.1 months vs. 6.8 months) and progression-free survival (6.4 months vs. 3.3 months). Despite the survival advantage, FOLFIRINOX was associated with increased toxicity, including a higher rate of febrile neutropenia. The findings suggest that FOLFIRINOX is a viable treatment option for patients with good performance s

Author

Yves Matos

Language

EN